To Report a Case of OSSN with an Excellent Surgical Outcome

Dr. Suryaprakash .A .V ¹ Dr. Pooja .B²

¹Professor, Department of Ophthalmology JJM Medical College Davanagere Karnataka

²Post Graduate in Ophthalmology

Abstract: Ocular surface squamous neoplasia (OSSN) represents a rare spectrum of disease ranging from mild dysplasia to carcinoma in situ to invasive squamous cell carcinoma of the ocular surface. OSSN is more common in elderly males, in countries closer to equator and countries where exposure to excessive sunlight is more common. Diagnosis of OSSN is mainly based on clinical suspicion. Definitive diagnosis needs histopathological evaluation. In this article, we report a case of OSSN in a 60 year old male patient.

Keywords: Cornea, Ocular Surface Squamous Neoplasia, OSSN, Conjunctival Auto graft, interferon

1. Introduction

Ocular surface squamous neoplasia (OSSN) represents a rare spectrum of disease ranging from mild dysplasia to carcinoma *in situ* to invasive squamous cell carcinoma of the ocular surface involving the conjunctiva and the cornea, occurring usually in the interpalpebral area, mostly at the limbus.¹

The aetiology of OSSN appears to be a multifactorial, and likely involves a variety of environmental factors in a susceptible host. Smoking and exposure to petroleum products have been implicated in the pathogenesis of OSSN.² other causes include:

Ultraviolet light: It is well recognized that the prevalence of OSSN is increased in populations that live within 30-degrees latitude from the equator.^{3,4} In addition, OSSN is more common in Caucasians with light complexions and patients with xeroderma pigmentosum, a genetic condition that increases susceptibility to DNA alterations secondary to UV light.⁵Furthermore, ocular lesions are most commonly located within the sun- exposed interpalpebral fissure, specifically in the nasal or temporal zones.²

Immunosuppression/ HIV:In Africa, studies have shown an HIV infection rate as high as 79% in patients with OSSN compared to 14% in the general population.⁶ In the United States, a study done at Bascom Palmer Eye Institute found that OSSN may be a possible marker for undiagnosed HIV. ³ The study found that half of patients diagnosed with OSSN under the age of 50 were seropositive for the virus.³ **Human papillomavirus (HPV):** The association of HPV with OSSN remains unclear. Although some studies have shown a clear association of OSSN with HPV, other studies have not.^{7,8}Whereas HPV 6,8, and 11 have been linked with benign conjunctival epithelial lesions, HPV 16 and 18 have been associated with malignant neoplastic lesions.² However, HPV status does not appear to correlate to treatment response.

Mutation or deletions of tumour suppressor gene **p53**:Mutations of p53, a tumour suppressor gene, are thought to be the most common genetic anomalies in human malignancies. ²Some have hypothesized that HPV or UV-B may alter p53, resulting in the development of OSSN in susceptible individuals.⁹

Clinically, the diagnosis is suspected by the appearance of epithelial changes of the ocular surface. Slit-lamp examination shows gelatinous, leukoplakic, papilliform or nodular lesions. Histopathological evaluation is essential for the definitive diagnosis and also to differentiate the three lesions in the spectrum of OSSN *i.e.*, epithelial dysplasia, carcinoma *in situ* and invasive squamous cell carcinoma.We report a case of OSSN in a 60-year old male

2. Case Report

A 60-year old male patient presented with the chief complaint of mass in his left eye since 3 months, which was progressively growing in size, and associated with redness. The patient had no history of trauma or surgery to that eye in the past. He had not taken any treatment for his left eye condition



General examination and systemic examination were normal He is a chronic smoker since 40 years

Best corrected visual acuity in his left eye was 6/9.

On local examination of the left eye, a greyish white nodular lesion of size 5.5 mm \times 5 mm was present at the limbus between 7°-8° clock position with presence of feeder vessels. The surface of the lesion was irregular.

Blood investigations were normal.

Serology test for HIV was negative.

Left eye ultrasonography was normal.



AS-OCT shows no involvement of the sclera and cilirary body

Surgical excision is the predominant modality of management for OSSN.¹⁰ The possibility of the lesion being malignant, further steps of treatment based on the pathology report and chances of recurrence of the lesion were discussed with the patient and informed written consent was taken.

Intra operatively: The mass was lying near the limbus and no involvement of the bowmen's membrane was seen.

Mass was excised along with 2mm of conjunctiva and a conjunctivalauto graft (3.5 x 5.5mm) was taken from supero

temporal side and placed on the bare sclera .And the specimen was sent for histopathological evaluation. Postoperatively patient was given topical antibiotic with steroid drops in a tapering dose.AS-OCT was repeated and reported to have no reoccurrence.

To prevent reoccurrence he was started on interferon $\alpha 2b$ eye drops one drop 4t/d for 3months.

3. Histopathology report showed



Hyperplastic stratified squamous epithelium with severe degree of dysplasia composed of atypical cells having irregular hyperchromatic nucleus with dense eosinophilic cytoplasm an occasional atypical mitosis.

And reported as: OCULAR SURFACE SQUAMOUS NEOPLASIA (CIN III)

Post-operative:

Volume 7 Issue 2, February 2018 www.ijsr.net

Licensed Under Creative Commons Attribution CC BY

International Journal of Science and Research (IJSR) ISSN (Online): 2319-7064 Index Copernicus Value (2016): 79.57 | Impact Factor (2015): 6.391



4. Discussion

Treatment of these tumours includes medical (IFN-a2b, mitomycin C [MMC], 5-fluorouracil [5-FU]), surgical or a combination of medical and surgical treatment .

The following table gives details of the chemo therapeutic a	gents:
--	--------

• Agent :	Mechanism of action :	Details of agent:
• Topical mitomycin C (MMC) is an antimetabolite	alkylates DNA and disrupts the production of RNA. ¹¹	MMC comes in either 0.02% or 0.04%. The lower concentration is usually prescribed continuously for a month; whereas, the higher concentration may be used for a week followed by 2 to 3 weeks off treatment. It must be refrigerated at +4 degree C. The disadvantages of MMC includes ocular pain, possible limbal stem cell loss, and other ocular surface toxicity. Punctal plug occlusion is advised to decrease the risk of punctual stenosis.
Interferon- $\alpha 2b$ (IFN $\alpha 2b$) is a cytokine produced by immune cells to combat microbes and viruses.	It's mechanism of action is thought to be related to its antiproliferative, cytotoxic, and antigenic properties. ¹¹	May be injected sub conjunctively or used topically as an eye drop. The concentration for the topical eye drop is 1 million IU/mL. The efficacy rate after topical IFN α 2b ranges from 80% to 100%. ¹² unfortunately, although well tolerated, IFN α 2b is only available through specialized compounding pharmacies & requires refrigeration.
• 5- fluorouracil (5-FU)	blocks DNA synthesis by acting as a pyrimidine analog after incorporation into RNA. ¹¹	Its efficacy rate has been reported to be 100% after one to five cycles (1 month on and 3 months off), with a recurrence rate of up to 20%. ¹³ Others prescribe it for 4 to 5 days every month; however, this dosing is associated with a higher recurrence rate. ¹⁴ The disadvantages of 5-FU include mild ocular irritation and occasional conjunctivitis.

Surgical

Surgical excision with "wide margin, no touch" technique is currently the best established form of treatment. Nevertheless, recurrences of these lesions are common after surgical excision, depending on the involvement of the surgical margins. Recurrence rates following excision of OSSN alone range from 15 to 52%, with an average of 30%. Recurrence rate is 5% when the surgical margins are free 53% when the surgical margins and are involved.¹⁵ Conjunctival defect can be closed primarily. Larger defects require either transpositonal conjunctival flaps, free conjunctival flaps from the other eye, or amniotic membrane grafts. Adjunctive therapy to reduce recurrence includes intra operative cryotherapy and brachytherapy, postoperative topical chemotherapy using mitomycin C, 5-FU and interferon alfa-2b.

Differential Diagnosis of OSSN

Corneal pannus

Medical management:

- Pterygium
- Pinguecculum
- Melanoma
- Conjunctival nevus •
- Dyskeratosis
- Pyogenic granuloma
- Keratoacanthoma
- Conjunctival lymphoma (salmon patch)

Prognosis

OSSN is a low grade malignancy with overall good prognosis and low incidence of lymph node or distant metastasis. Most significant prognostic factor for recurrence is presence of neoplastic cell in margins after tumour excision.

Volume 7 Issue 2, February 2018 www.ijsr.net

Licensed Under Creative Commons Attribution CC BY

References

- [1] Basti A, Macsai MS. Ocular surface squamous neoplasia: A review. Cornea 2003;22:687-704
- [2] Krachmer JH, Mannis MJ, Holland EJ. Cornea: Fundamentals, diagnosis and management. 2005.
- [3] Karp CL, Scott IU, Chang TS, Pflugfelder SC. Conjunctival Intraepithelial Neoplasia: A Possible Marker for Human Immunodeficiency Virus Infection? Arch Ophthalmol 1996;114:257–261.
- [4] Basti S, Macsai MS. Ocular surface squamous neoplasia: a review. Cornea 2003;22:687–704.
- [5] Lee GA, Williams G, Hirst LW, Green AC. Risk factors in the development of ocular surface epithelial dysplasia. Ophthalmology 1994;101:360–364
- [6] Spitzer MS, Batumba NH, Chirambo T, et al. Ocular surface squamous neoplasia as the first apparent manifestation of HIV infection in Malawi. Clin Experiment Ophthalmol 2008;36:422–425.
- [7] Carrilho C, Gouveia P, Yokohama H, et al. Human papillomaviruses in intraepithelial neoplasia and squamous cell carcinoma of the conjunctiva. European Journal of Cancer Prevention 2013;22:566–568.
- [8] Galor A, Garg N, Nanji A, et al. Human Papilloma Virus Infection Does Not Predict Response to Interferon Therapy in Ocular Surface Squamous Neoplasia. Ophthalmology 2015;122:2210–2215.
- [9] Kiire CA, Srinivasan S, Karp CL. Ocular Surface Squamous Neoplasia. International ophthalmology clinics 2010;50:35–46.
- [10] Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors: The 1994 Lynn B. McMahan Lecture. Arch Ophthalmol 1997;115:808-15.
- [11] Nanji AA, Sayyad FE, Karp CL. Topical chemotherapy for ocular surface squamous neoplasia. Curr Opin Ophthalmol 2013;24:336–342.
- [12] Galor A, Karp CL, Chhabra S, et al. Topical interferon alpha 2b eye-drops for treatment of ocular surface squamous neoplasia: a dose comparison study. British Journal of Ophthalmology 2010;94:551–554.
- [13] Midena E, Angeli CD, Valenti M. Treatment of conjunctival squamous cell carcinoma with topical 5fluorouracil. British journal of Ophthalmology 2000;84:268–272.
- [14] Yeatts RP, Engelbrecht NE, Curry CD, et al. 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. Ophthalmology 2000;107:2190–2195.
- [15] Erie JC, Campbell RJ, Liesegang TJ. Conjunctival and corneal intraepithelial and invasive neoplasia. Ophthalmology 1986;93:176-83.

Volume 7 Issue 2, February 2018 <u>www.ijsr.net</u> Licensed Under Creative Commons Attribution CC BY